(Q38245819)

31 August 2017

title

Polymeric anti-HIV therapeutics (English)

1 reference

31 August 2017

publication date

3 September 2014

1 reference

Macromolecular Bioscience

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185484%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185484%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185484%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

9-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25185484%20AND%20SRC:MED&resulttype=core&format=json

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Antiretroviral resistance during successful therapy of HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Structural biology of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Distribution and three-dimensional structure of AIDS virus envelope spikes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

21 January 2018

V3: HIV's switch-hitter

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Revisiting HIV-1 uncoating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Active nuclear import of human immunodeficiency virus type 1 preintegration complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Nucleocytoplasmic transport: the last 200 nanometers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Antiretroviral therapy and management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

HIV-1 inhibition by a peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Atomic structure of the ectodomain from HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

The dawning era of polymer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Critical design features of phenyl carboxylate-containing polymer microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Chemotherapeutic interventions targeting HIV interactions with host-associated carbohydrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Novel sulfated polymers as highly potent and selective inhibitors of human immunodeficiency virus replication and giant cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

"Viologen" dendrimers as antiviral agents: the effect of charge number and distance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Peptide and protein PEGylation: a review of problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Site-specific polymer attachment to a CCL-5 (RANTES) analogue by oxime exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

The entry of entry inhibitors: a fusion of science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Modular assembly of dimeric HIV fusion inhibitor peptides with enhanced antiviral potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

PEGylation of cyanovirin-N, an entry inhibitor of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis, drug release and anti-HIV activity of a series of PEGylated zidovudine conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

DC-SIGN: escape mechanism for pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dendritic-cell interactions with HIV: infection and viral dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Sequence-controlled multi-block glycopolymers to inhibit DC-SIGN-gp120 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

A general glycomimetic strategy yields non-carbohydrate inhibitors of DC-SIGN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dextran sulfate is poorly absorbed after oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Setting the stage: host invasion by HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Living Free-Radical Polymerization by Reversible Addition−Fragmentation Chain Transfer: The RAFT Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Living Radical Polymerization by the RAFT Process ? A Third Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Atom Transfer Radical Polymerization (ATRP): Current Status and Future Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Nitroxide-mediated polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Synthesis of anionic carbosilane dendrimers via “click chemistry” and their antiviral properties against HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Side-Chain Peptide-Synthetic Polymer Conjugates via Tandem “Ester-Amide/Thiol–Ene” Post-Polymerization Modification of Poly(pentafluorophenyl methacrylate) Obtained Using ATRP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298

Dissecting carbohydrate–Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMABI.201400298